Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)

The QualityStocks Daily Newsletter would like to spotlight Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).

Tonix Pharmaceuticals (NASDAQ: TNXP) announced that CEO Seth Lederman, M.D., will present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025, at 3:30 p.m. ET. The live, interactive event will allow investors to engage with the company in real-time, with an archived webcast available afterward on the company's website.

To view the full press release, visit https://ibn.fm/RTiwx

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a fully-integrated biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics aimed at treating and preventing human diseases and alleviating suffering. The company’s development portfolio is primarily focused on central nervous system (CNS) disorders, with its lead product candidate, TNX-102 SL, showing significant promise for the management of fibromyalgia. With two successful Phase 3 studies completed, Tonix is preparing to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, which has also been granted Fast Track designation. In addition to fibromyalgia, TNX-102 SL is being developed to treat acute stress reactions, further broadening its therapeutic potential.

Tonix’s CNS portfolio also includes TNX-1300, a biologic designed to treat cocaine intoxication, which has been granted Breakthrough Therapy designation by the FDA. This designation underscores the urgency and significance of developing an effective treatment for cocaine intoxication, a critical need in the healthcare system. Beyond CNS disorders, Tonix is expanding its immunology portfolio with the development of TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154). TNX-1500 is being developed for the prevention of allograft rejection and the treatment of autoimmune diseases, highlighting Tonix’s commitment to addressing complex and challenging medical conditions.

In addition to its robust pipeline, Tonix has an established commercial presence through its subsidiary, Tonix Medicines, which markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine in adults. The company’s diverse portfolio, spanning CNS disorders, immunology, rare diseases, and infectious diseases, positions Tonix as a leader in biopharmaceutical innovation, with a strong focus on developing therapies that address unmet medical needs and improve patient outcomes.

TNX-102 SL

TNX-102 SL is a groundbreaking, non-opioid, non-addictive investigational drug developed by Tonix Pharmaceuticals for the management of fibromyalgia where patients suffer chronic musculoskeletal pain, sleep deprivation, fatigue and mood changes. This patented sublingual formulation of cyclobenzaprine hydrochloride has demonstrated remarkable efficacy in clinical trials, including the recent RESILIENT Phase 3 trial, where it achieved highly statistically significant results in reducing daily pain compared to placebo (p=0.00005). The drug also showed significant improvements in sleep quality, fatigue reduction, and overall fibromyalgia symptoms and function across all key secondary endpoints. With similar success in the earlier RELIEF Phase 3 trial, TNX-102 SL is positioned as a promising new treatment option for fibromyalgia, particularly given its favorable safety profile, where the most common side effect was mild and self-limiting tongue or mouth numbness.

Recently granted Fast Track Designation by the FDA, TNX-102 SL is on course for a New Drug Application (NDA) submission in the second half of 2024. This designation highlights the urgent need for new fibromyalgia treatments and underscores the drug’s potential to effectively address this challenging condition. With its strong clinical results and focus on improving multiple aspects of fibromyalgia, TNX-102 SL offers hope for patients seeking better management of their symptoms and represents a significant advancement in the treatment landscape for this debilitating disorder.

Market Opportunity

From an investment perspective, Tonix Pharmaceuticals is strategically positioned to capitalize on the growing demand for effective treatments in the central nervous system (CNS) disorder market, particularly within the fibromyalgia segment, which is estimated to affect up to 10 million people in the U.S. alone. With the potential approval of TNX-102 SL, Tonix could tap into a significant and underserved market, offering a non-opioid alternative for a condition that currently has limited treatment options. The recent positive results from the Phase 3 trials and the FDA’s Fast Track designation increase the likelihood of TNX-102 SL gaining market approval, which could significantly boost Tonix’s market share and revenue potential.

In addition to its lead candidate, Tonix’s diversified pipeline, which includes treatments for conditions such as cocaine intoxication and autoimmune diseases, broadens market opportunities and reduces single product dependency. The company’s established commercial presence with its migraine treatments, combined with the advancement of its CNS and immunology portfolios, positions Tonix to become a key player in the biopharmaceutical industry. As the company moves closer to potential product launches and reached new clinical milestones, it stands to attract substantial investor interest, offering significant upside potential as it addresses critical unmet needs across multiple therapeutic areas.

Leadership Team

Dr. Seth Lederman is the Co-Founder, CEO, and Chairman of Tonix Pharmaceuticals, bringing decades of experience in the biotechnology and pharmaceutical industries. A trained physician and scientist, Dr. Lederman has been instrumental in leading Tonix’s strategic direction and advancing its pipeline of innovative therapeutics. He has a strong background in immunology and infectious diseases, with numerous contributions to medical research and drug development. Dr. Lederman earned his MD from Columbia University, where he also served as an Associate Professor.

Dr. Gregory Sullivan is the Chief Medical Officer of Tonix Pharmaceuticals, where he oversees the clinical development and regulatory strategy for the company’s therapeutic programs. With extensive experience in psychiatry and CNS disorders, Dr. Sullivan plays a key role in guiding Tonix’s clinical trials and ensuring the scientific rigor of its development efforts. Before joining Tonix, Dr. Sullivan had a distinguished career in academic medicine and clinical research. He holds an MD from the University of California, San Francisco, and has published widely on topics related to psychiatry and neurological disorders.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), closed Tuesday's trading session at $13.63, up 1.1878%, on 21,641 volume. The average volume for the last 3 months is 1,977,825 and the stock's 52-week low/high is $6.76/$1193.28.

Recent News

• Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) - BioMedNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at Zacks SCR Life Sciences Virtual Forum 
• BioMedNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures MCDC Grant for TNX-801 Smallpox and Mpox Vaccine Development 
• InvestorNewsBreaks - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 Virtual Investor Summit

NanoViricides Inc. (NYSE American: NNVC)

The QualityStocks Daily Newsletter would like to spotlight NanoViricides Inc. (NYSE American: NNVC).

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage company developing broad-spectrum antiviral drugs, announced that its business remains unaffected by U.S. tariff policies and government spending cuts. The company reaffirmed its focus on antiviral treatments rather than vaccines, citing strong potential for its lead candidate, NV-387, in treating measles, MPox, influenza, and COVID-19. NanoViricides is preparing a Phase II clinical trial for NV-387 in MPox and advancing NV-HHV-1 for herpesvirus infections. Leadership believes NNVC presents a long-term investment opportunity despite recent stock market volatility.

To view the full press release, visit https://ibn.fm/nm0k1

NanoViricides Inc. (NYSE American: NNVC) is a clinical stage global leader in the development of nanomedicine drugs against viruses. Going beyond what antibodies and immunotherapeutics do, the company’s unique nanoviricide® platform technology is designed to specifically target and dismantle enveloped virus particles, offering a novel approach to treating a wide range of viral infections. NanoViricides’ lead drug candidate, NV-387, is being developed for the treatment of respiratory viral infections, including RSV, COVID-19, Long COVID, and Influenza, with the company currently advancing NV-387 into Phase II human clinical trials. Another advanced candidate, NV-HHV-1, targets Shingles and represents a significant step forward in the treatment of viral diseases.

NanoViricides has also developed drug candidates specifically for COVID-19, including NV-CoV-2, which is composed of the NV-387 active pharmaceutical ingredient, and NV-CoV-2-R, which incorporates remdesivir, an FDA-approved antiviral, within its polymeric micelles. The company believes that NV-CoV-2-R has strong potential for approval, given the established safety profile of remdesivir. NanoViricides’ platform technology, based on the TheraCour® nanomedicine technology licensed from TheraCour Pharma, Inc., provides broad, exclusive, and sub-licensable field licenses for various viral diseases.

Beyond its focus on respiratory infections, NanoViricides is developing treatments for a range of other viral diseases, including oral and genital herpes, viral eye diseases, H1N1 and H5N1 influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. The company’s technology platform is built on a solid foundation of licensing agreements with TheraCour Pharma, Inc., which allows NanoViricides to access and develop therapies targeting specific viruses. With its broad pipeline and innovative approach, NanoViricides aims to play a leading role in the development of next-generation antiviral therapies.

NV-387

NanoViricides is advancing its lead drug candidate, NV-387, a novel broad-spectrum antiviral designed to mimic the ubiquitous sulfated-proteoglycan (S-PG) features that over 90% of pathogenic human viruses utilize to infect human cells. NV-387 has demonstrated superior or equivalent efficacy compared to existing drugs in non-clinical animal trials against three major classes of viruses: Influenza, COVID-19, and RSV. Notably, in an RSV efficacy study, NV-387 provided complete survival and full lung protection in lethally infected mice, indicating its potential as a groundbreaking treatment where no effective options currently exist. The broad-spectrum effectiveness of NV-387 across multiple viral families suggests a highly robust antiviral agent that could potentially address the challenge of viral resistance, setting it apart from traditional medical countermeasures like vaccines, antibodies, and small molecule antivirals.

Currently, NanoViricides is completing a database audit and an external technical audit of its Phase 1a/1b human clinical trial of NV-387 in healthy subjects, with the goal of advancing to a Phase II clinical trial aimed at evaluating the drug’s antiviral effectiveness in humans. The company is also exploring innovative clinical trial designs that could allow for the simultaneous evaluation of NV-387’s efficacy against multiple respiratory viruses, which would be a significant advancement in clinical science. With the potential to address a market size estimated to exceed $12 billion within the next three years, NanoViricides is making substantial progress towards the commercialization and market entry of NV-387, while also seeking big pharma collaborations to expedite its programs and secure additional financing.

Market Opportunity

From an investment perspective, NanoViricides is positioned to capitalize on the growing demand for broad-spectrum antiviral therapies, particularly as the world continues to grapple with emerging and re-emerging viral threats. The company’s innovative approach, using nanomaterials to directly target and dismantle viruses, offers a unique and potentially disruptive solution in a market traditionally dominated by vaccines and small molecule antivirals. With a focus on respiratory viruses, which are a significant global health concern, NanoViricides addresses critical unmet needs that could result in substantial market penetration and revenue growth, especially as governments and health organizations seek more effective countermeasures against viral pandemics.

Additionally, the versatility of NanoViricides’ platform technology provides significant potential for expansion into multiple viral indications beyond its current focus areas. This adaptability not only enhances the company’s ability to address a broader range of viral infections but also diversifies its revenue streams, reducing reliance on any single market. As global health challenges evolve, NanoViricides’ capacity to quickly develop and scale antiviral therapies tailored to various viruses positions the company as a compelling investment opportunity with the potential for significant returns, particularly as it advances its clinical programs and moves closer to commercialization.

Leadership Team

Dr. Anil R. Diwan is the President and Chairman of NanoViricides, which he co-founded in 2005. A prolific inventor and serial entrepreneur, Dr. Diwan has over 25 years of experience in biopharmaceutical R&D and has played a pivotal role in the company’s growth, including leading its 2013 uplisting to NYSE-American and spearheading various financing efforts. He is the inventor of novel polymeric micelle-based nanomedicine technologies and has founded multiple companies, including TheraCour Pharma, Inc. and AllExcel, Inc. Dr. Diwan holds a Ph.D. from Rice University and a B.Tech. from the Indian Institute of Technology, Mumbai (IIT-B), and was recognized as “Researcher of the Year” by BusinessNewHaven in 2014.

Ms. Meeta R. Vyas is the interim Chief Financial Officer of NanoViricides, bringing over 25 years of experience in finance, operations, and strategy across a diverse range of organizations, including publicly listed companies and non-revenue generating entities. She holds the distinction of being the first Indian woman to serve as CEO of a publicly listed U.S. corporation, Signature Brands, Inc., where she successfully led a turnaround strategy. Ms. Vyas has held senior leadership roles at the World-Wide Fund for Nature – India, the National Audubon Society, and General Electric (GE). She holds an MBA in Finance from Columbia University and a BS in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

NanoViricides Inc. (NYSE American: NNVC), closed Tuesday's trading session at $1.29, up 11.2069%, on 210 volume. The average volume for the last 3 months is 284,538 and the stock's 52-week low/high is $1.0297/$3.59.

Recent News

• NanoViricides Inc. (NYSE American: NNVC) - InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights Antiviral Pipeline, Positions Stock as Market Hedge
• InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Measles Treatment Amid Outbreak
• InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Claims NV-387 Ready to Combat Bird Flu

Torr Metals Inc. (TSX.V: TMET)

The QualityStocks Daily Newsletter would like to spotlightFathom Torr Metals Inc. (TSX.V: TMET) .

Torr Metals Inc. (TSX.V: TMET) announced it has signed an option agreement, pending TSX Venture Exchange approval, to acquire 100% of the 57 km² Bertha Property, which is adjacent to the northern portion of its Kolos Project. The acquisition, along with additional claim staking, increases the Kolos Project's footprint to 332 km² in a prolific British Columbia mining district. The Bertha Property contains nine copper and gold occurrences, with high-grade samples and drill-permitted targets. Torr plans a 2025 drill program to advance exploration efforts and define new copper-gold discoveries.

To view the full press release, visit https://ibn.fm/RLmI1

Torr Metals Inc. (TSX.V: TMET) operates as a mineral exploration company focusing on the identification, acquisition, and advancement of mineral properties. With full 100% ownership of over 1,000 square kilometers of gold and copper projects strategically positioned in premier low-cost mining jurisdictions, Torr is poised for substantial returns across various promising regions.

The company’s extensive portfolio encompasses multiple district-scale projects, including the Filion Gold Project in northern Ontario, the Kolos Copper-Gold Project in south-central British Columbia, and the Latham Copper-Gold Project in northern British Columbia. These projects are all located in prolific mining regions with paved highway access, robust support infrastructure, and favorable geological conditions offering significant potential for new discoveries.

Headquartered in Vancouver, British Columbia, Torr Metals is ideally situated to leverage its expertise and resources for continued exploration and growth.

Projects

Kolos Copper-Gold Project

Situated within British Columbia’s prime copper-producing belt, the 140-square-kilometer Kolos Copper-Gold Project exhibits Nicola Belt geology similar to notable porphyry mines, including Copper Mountain and Highland Valley, respectively situated 106 kilometers to the south and 30 kilometers to the northwest.

With field operations based in the nearby city of Merritt and year-round access provided via Highway 5, the Kolos Project showcases substantial discovery upside potential with five defined large-scale copper-gold-molybdenum anomalies untested by drilling.

Torr Metals’ primary focus lies in unlocking the potential for major new discoveries at the Kolos Copper-Gold Project, with recent surface geochemical results marking a significant milestone positioning the company as a new key player in the region.

Filion Gold Project

The 261-square-kilometer Filion Project is situated within a largely unexplored greenstone belt where gold was initially discovered in the 1930s. With a comparable geological setting to regional orogenic gold deposits and multiple newly identified and undrilled gold trends in surficial geochemistry, the Filion Project holds significant district-scale exploration promise.

The Filion Project benefits from unparalleled infrastructure access, with direct drive-on access from the Trans-Canada Highway, as well as a regional railway and power grid four kilometers to the south. Additionally, the nearby town of Kapuskasing, with a population of 8,300, provides essential support services.

This strategic positioning ensures the Filion Project’s viability for cost-effective, year-round operations in an area poised for untapped discovery potential.

Latham Copper-Gold Project

Situated in British Columbia’s renowned Golden Triangle, the Latham Project spans a vast 689-square-kilometer district, offering immense potential for multiple major discoveries. Accessible year-round via Highway 37, just 20 kilometers south of the town of Dease Lake, the site is strategically located amidst established mining infrastructure, including the active Red Chris mine to the southeast and upcoming major porphyry projects at Schaft Creek and Galore Creek along-trend to the southwest.

Highlighted by the Gnat Pass copper-gold porphyry deposit dating back to the 1960s, the Latham Project presents a compelling opportunity for significant expansion and potential discovery. A non-compliant indicated resource at the Gnat Pass deposit includes 33 million tonnes at 0.39% copper, open beyond 200 meters vertical depth, alongside six drill-ready kilometer-scale copper-gold exploration targets.

Moreover, the Latham Project’s appeal corresponds to the region being an attractive destination for major asset acquisitions and takeovers. Recent transactions within a 40-kilometer radius include Newmont’s 2021 acquisition of the Saddle North copper-gold porphyry deposit for $311 million and Newcrest’s investment in the Red Chris copper-gold porphyry deposit in 2019 for $804 million, underscoring industry acknowledgment of the region’s potential.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 that the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Likewise, a report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Malcolm Dorsey, P.Geo., is President, CEO and Director of Torr Metals. He brings over a decade of expertise as a seasoned exploration geologist and project developer, having been pivotal in driving the success of numerous diverse projects across North, Central, and South America. His comprehensive background spans early-stage exploration through to resource development and project acquisitions. His academic credentials include an M.Sc. in Geology and Geophysics from the University of Calgary, where his research characterized the district-scale structural influences affecting copper and gold mineralizing events in western British Columbia. Prior to his current role, he served as Senior Geologist for Benchmark Metals, where his contributions were instrumental in advancing the company’s gold equivalent resource from approximately 80,000 ounces to a maiden resource estimate of 2.92 million ounces.

John Williamson, P. Geol., is Chairman and Director of Torr Metals. He is a mining executive and investor with more than 30 years of experience as a founder, promoter and leader in the formation, financing and operation of private and public companies with exploration and mining interests worldwide. On more than one occasion his team’s efforts have been recognized for excellence by being named to the TSX Venture 50. He holds a B.Sc. in Geology and is a registered Professional Geologist (P.Geol.) with the Association of Professional Engineers and Geoscientists (APEGA) and the Geological Association of Canada.

Torr Metals Inc. (TSX.V: TMET), closed Tuesday's trading session at $23.99, up 2.3163%, on 123 volume. The average volume for the last 3 months is 390 and the stock's 52-week low/high is $21.39/$31.9.

Recent News

• Torr Metals Inc. (TSX.V: TMET) - RockBreaks - Torr Metals Inc. (TSX.V: TMET) Expands Kolos Project With Bertha Property Acquisition 
• RockBreaks - Torr Metals Inc. (TSX.V: TMET) Identifies Multiple Gold Targets at Filion Gold Project
• MiningNewsBreaks - Torr Metals Inc.'s (TSX.V: TMET) Kolos Project Poised to Support Growing Copper Demand

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Annovis Bio Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer's & Parkinson's Drug Development Summit from March 18-20 in Boston. CEO Maria Maccecchini, Ph.D., will present Phase III data on buntanetap and discuss a holistic approach to targeting neurotoxic proteins on March 19. Annovis will also join a panel on advancing Parkinson's therapies, emphasizing the need for broader treatment strategies beyond single-target approaches.

To view the full press release, visit https://ibn.fm/nyW4N

Annovis Bio Inc. Overview

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as AD and PD. Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach addresses both the cognitive decline in AD and the motor dysfunction in PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly known as Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a 3.3 point improvement compared to 0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating buntanetap’s mechanism of action.

Similarly, in the recently completed Phase III study of buntanetap in patients with early PD, buntanetap significantly improved disease-related daily non-motor and motor functions in Parkinson’s patients who had a diagnosis over 3 years as well as improved cognition in all PD patients. It further underscores buntanetap’s potential as a transformative therapy.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050​ (Alzheimer’s Association)​​ (Republican Policy Committee)​. Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease​ (SingleCare)​.

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050​​. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

• Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
• Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
• Groundbreaking Clinical Insights: Recent Phase III data in Parkinson’s Disease patients demonstrates significant improvements in motor and cognitive functions.
• Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate buntanetap’s disease-modifying potential.
• Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

• Maria L. Maccecchini, Ph.D. – Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.
• Cheng Fang, Ph.D. – Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.
• Michael Christie, Ph.D. – VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.
• Melissa Gaines – Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Annovis Bio Inc. (NYSE: ANVS), closed Tuesday's trading session at $1.6, even for the day, on 266 volume. The average volume for the last 3 months is 565,762 and the stock's 52-week low/high is $1.525/$20.

Recent News

• Annovis Bio Inc. (NYSE: ANVS) - BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer's & Parkinson's Drug Development Summit 
• Scientists Say Brain Stimulations Hold Potential in Treating Anxiety in Parkinson’s Sufferers
• BioMedNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer's and Parkinson's Trials

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Graphite plays a vital role in next-gen nuclear technology. For instance, in nuclear reactors operating at high temperatures and relying on gas cooling, graphite is used to enclose and encapsulate the nuclear fuel. This helps to improve the safety of a nuclear reactor in the event that the cooling system fails. This is the reason why vendors of nuclear energy systems are required to show that the grade of graphite they plan to use can withstand not just the heat but other environmental conditions inside a reactor. A new model that has been developed by a team at Idaho National Laboratory could make it easier for vendors to prove to licensing authorities that their graphite of choice will do the job that it is expected to perform in a nuclear facility. They then compared the curves that the computer simulation generated to the curves that were obtained from previous actual tests of graphite grades. The simulations were so accurate that it was hard to choose which curve was a result of the computer model's work and which one was obtained after conducting actual tests. This model is going to make it easier for vendors of nuclear technology to have their systems qualified/approved by regulatory bodies. As such modeling systems are deployed, entities like Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) focusing on graphite production could see increased investor interest over the coming years if more nuclear plants come online sooner as the approval process is expedited by better modeling systems.

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.

Projects

Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Tuesday's trading session at $0.0362, even for the day, on 3,000 volume. The average volume for the last 3 months is 3,700 and the stock's 52-week low/high is $0.0077/$0.125.

Recent News

• Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) - New Graphite Modeling Approach Could Expedite Licensing
• Green Energy Investment is Showing Mismatched Priorities
• The Energy Industry is Growing Doubtful of the Attainability of Net Zero Targets

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

Greenwashing refers to the practice of making deceptive or false claims about a firm's products or practices and whether they are safe for the environment. Recent data shows that greenwashing incidents have risen significantly over the past 4 years, with an increasing number of sustainability claims found to be false. Figures from last year indicate that over 900 companies were linked to greenwashing incidents, particularly in the banking and financial services, food and beverage, and oil and gas sectors. From the above, we can deduce that anti-greenwashing rules and ESG standards are increasingly being seen as tools to help shape company behavior. It is expected that as more greenwashing cases are tried in courts of law, more firms will endeavor to be honest and transparent about their sustainability claims. The rising number of lawsuits on alleged greenwashing by companies is likely to provide added impetus for firms like Energy and Water Development Corp. (OTCQB: EAWD) to have verifiable records documenting their implementation of ESG principles so that they remain blemish-free.

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Tuesday's trading session at $0.0025, even for the day, on 482,022 volume. The average volume for the last 3 months is 1,288,120 and the stock's 52-week low/high is $0.0012/$0.099.

Recent News

• Energy and Water Development Corp. (OTCQB: EAWD) - Courts are Holding More Firms Accountable as Greenwashing Incidents Increase
• Key Trends Driving the Renewable Energy Certificate Market
• Report Calls Out Europe for Using African Renewable Energy for Greenwashing

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

A recent study whose findings appeared in the Nature Communications journal has shown that a new experimental drug can increase the survival time of patients who have been diagnosed with glioblastoma. This brain cancer is the most prevalent brain cancer in adults. The experimental drug, dubbed 186RNL (Rhenium Obisbemeda), was developed at UT Health San Diego. The trial established that this drug candidate, at the very least, doubled the progression-free and survival duration of study participants in comparison to the known progression-free or survival rates of patients afflicted by this brain tumor. It also didn't have any side effects that would limit the dosage given to a patient. The researchers noted that after the drug was administered, patients spent at least 6 months without their condition progressing. They also had an improved survival time of 17 months compared to just 8 months maximum for patients receiving other existing treatments. The best results were obtained from study participants who received doses higher than 100 Gray (a ‘Gray' is a standard unit used to measure radiation). The adverse effects noted were found to be resulting from factors which weren't connected to the treatment. Many more companies, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP), are conducting their own programs aimed at commercializing new drugs targeting brain and central nervous system cancers, such as glioblastoma. Their success will increase the treatment options for people suffering from these diseases.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $2.5, off by 3.8462%, on 1,973 volume. The average volume for the last 3 months is 898,637 and the stock's 52-week low/high is $2/$1150.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Study Finds Experimental Drug Prolongs the Survival of Glioblastoma Patients
• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress
• BioMedNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

After surpassing the U.S. to become the largest greenhouse gas emitter on the planet for well over a decade, China is working hard to expand its renewable energy capacity. Even though China still produces more emissions than any other country, Beijing's massive investments in green energy have made the East Asian country a powerhouse in the nascent green energy industry. The National Development and Reform Commission (NDRC) recently announced that China would invest in major green energy projects to create massive renewable energy bases that use both wind and solar farms to generate clean energy on a large scale. This marks Beijing's latest thrust into renewable energy and builds on the country's recent history of advancing clean energy projects. Beijing announced in 2020 that it would hit peak carbon emissions by the end of the decade and achieve carbon neutrality by 2060. In the years since, China has achieved its goal of doubling domestic green energy capacity six years ahead of schedule and now attracts most of the world's green energy investment. As China's installed renewables capacity continues to soar, other technologies, such as electric vehicles from manufacturers like Mullen Automotive Inc. (NASDAQ: MULN), will compound to accelerate the reversal of climate change drivers, especially in the transportation sector.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $1.08, off by 13.6%, on 223,193 volume. The average volume for the last 3 months is 5,018,412 and the stock's 52-week low/high is $1.02/$47100.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - Blighted by Its Heavy Pollution Record, China Doubles Down on Renewables
• EU Automakers Get Pollution Targets Breather as EV Sales Falter
• BP Ditches its Clean Energy Ambitions, Doubles Down on Fossil Fuels

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) successfully hosted its first Investor Weekend at its Italian Serie B football club, SS Juve Stabia, in Castellammare di Stabia. The event provided investors with an immersive experience, including attending Juve Stabia's match against Cittadella, engaging with club executives, and exploring Naples' rich cultural and football heritage. Investors also visited the Juve Stabia Academy and attended a Serie A match between Inter Milan and Napoli. Brera plans to expand these investor-focused experiences to strengthen engagement and support its multi-club ownership strategy.

To view the full press release, visit https://ibn.fm/oXVB7

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Tuesday's trading session at $0.6621, off by 13.451%, on 1,443 volume. The average volume for the last 3 months is 3,429,758 and the stock's 52-week low/high is $0.4999/$1.95.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Hosts Inaugural Investor Weekend at Juve Stabia
• TinyGemsBreaks - Brera Holdings PLC (NASDAQ: BREA) Adds Economist Arthur Laffer to Advisory Board 
• Brera Holdings PLC (NASDAQ: BREA) Marks New Chapter with Signed LOI to Invest in Mozambican Moçambola 2024 Champion Black Bulls

NEWTON GOLF Company (NASDAQ: SPGC)

The QualityStocks Daily Newsletter would like to spotlight NEWTON GOLF Company (NASDAQ: SPGC).

Newton Golf (Nasdaq: SPGC) , formerly Sacks Parente Golf, has officially changed its corporate name to better align with its commitment to golf technology innovation. The rebranding reflects the company's focus on advanced physics and precision engineering in golf equipment. Additionally, the company's Board of Directors has approved a 1-for-30 reverse stock split, effective at the market open on March 17, 2025, when its common stock will begin trading under the new ticker symbol "NWTG" on the Nasdaq Capital Market.

To view the full press release, visit https://ibn.fm/XqxL4

NEWTON GOLF Company (NASDAQ: SPGC), a Sacks Parente Company, is a technology-forward golf equipment manufacturer committed to enhancing player performance through innovative design. Since its founding in 2018, the company has developed a growing portfolio of premium golf products, including putters, golf shafts, grips, and related accessories. Its proprietary advancements include the First Vernier Acuity putter, patented Ultra-Low Balance Point (ULBP) technology, weight-forward Center-of-Gravity (CG) design, and ultra-light carbon fiber putter shafts.

As part of its commitment to growth in golf shaft technologies, the company expanded its manufacturing operations in April 2022, opening a dedicated facility in St. Joseph, Missouri. This move reinforced its goal of maintaining high-quality production standards while manufacturing and assembling substantially all of its products in the United States. In addition to golf clubs and accessories, NEWTON GOLF is exploring expansion into golf apparel and other product categories.

The company sells its products through multiple channels, including resellers, its direct-to-consumer website, Club Champion retail stores, and distributors in the U.S., Japan, and South Korea. Future expansion may include growth through mergers, acquisitions, or the development of complementary product lines.

NEWTON GOLF Company is headquartered in Camarillo, California.

Products

NEWTON GOLF is focused on delivering high-performance golf equipment with a strong emphasis on precision engineering and cutting-edge materials. The company’s key product lines include:

• Newton Motion Golf Shafts: Launched in November 2023, these shafts are engineered with proprietary flex profiles designed for greater distance, reduced dispersion, and optimized performance across swing speeds. The company’s DOT system eliminates traditional shaft flex definitions, making it accessible to all golfers.
• Gravity Putters: Introduced in October 2024, these putters incorporate patented Ultra-Low Balance Point (ULBP) technology to improve stroke consistency and tighten putt dispersion. Manufactured in the U.S., they feature premium materials such as steel, aluminum, titanium alloys, and patented magnesium face plate technology.
• Golf Grips & Accessories: The company continues to innovate in this category, providing golfers with performance-enhancing grips and accessories to complement their clubs.

All NEWTON GOLF products are manufactured with strict quality control standards to ensure precision and reliability, reinforcing the brand’s reputation for premium performance.

Market Opportunity

The global golf equipment market was valued at approximately $8 billion in 2022, with the U.S. market accounting for $2.9 billion. The golf club segment dominated the industry, representing 45.7% of total market share. Increasing participation in golf, particularly among younger players and women, is driving demand for high-quality, customizable golf equipment.

Key industry trends supporting growth include:

• The increasing popularity of premium, high-performance golf equipment among both professionals and amateurs.
• A shift toward customization, as golfers seek tailored products that enhance performance.
• A growing interest in golf from younger demographics, with amateur and collegiate golfers being particularly receptive to innovation.

NEWTON GOLF’s emphasis on U.S.-based manufacturing provides it with a competitive edge in terms of supply chain efficiency, quality control, and sustainability, further strengthening its position in the market.

Leadership Team

Dr. Greg Campbell, Executive Chairman and Chief Executive Officer, brings nearly 40 years of experience in emerging technologies, product development, and public company leadership. He currently serves as CEO of V-Grid Energy Systems, a California-based company focused on converting agricultural waste into renewable electricity and bio-carbon. He has successfully taken two companies public and previously managed a $1.2 billion P&L as SVP & GM at Lam Research. Campbell holds a Ph.D. in Electrical and Electronics Engineering from UCLA and a BA/MA in Engineering from Cambridge University.

Ryan Stearns, Chief Financial Officer, was appointed in 2024 and oversees financial planning and corporate strategy. He brings expertise in scaling businesses and optimizing financial performance to support the company’s growth.

NEWTON GOLF Company (NASDAQ: SPGC), closed Tuesday's trading session at $0.107, off by 33.1668%, on 981,243 volume. The average volume for the last 3 months is 29,394,107 and the stock's 52-week low/high is $0.09/$6.69.

Recent News

• NEWTON GOLF Company (NASDAQ: SPGC) - Newton Golf Company (NASDAQ: SPGC) Invigorates Future of Golf with Innovative Equipment, Customer Engagement
• InvestorNewsBreaks - Why NEWTON GOLF Company (NASDAQ: SPGC) Is 'One to Watch'
• NEWTON GOLF Company (NASDAQ: SPGC) Is 'One to Watch'

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) announced further assay results from its definition diamond drilling program at the Iska Iska silver-tin polymetallic project in Bolivia, highlighting the highest-grade silver intersection recorded in the program. Hole DSB-75 returned 135 meters grading 151.47 g/t silver within a broader 309-meter section at 90.92 g/t silver. A high-grade interval within this hole included 962.23 g/t silver over 9.75 meters, suggesting greater mineralization potential. The company is accelerating infill and step-out drilling to refine high-grade zones for its next phase of economic assessment.

To view the full press release, visit https://ibn.fm/CL3z4

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Tuesday's trading session at $0.6305, up 2.7375%, on 85,076 volume. The average volume for the last 3 months is 65,500 and the stock's 52-week low/high is $0.547/$1.39.

Recent News

• Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) - InvestorNewsBreaks - Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports Highest-Grade Silver Intersection at Iska Iska Project
• Musk's DOGE Targets Fort Knox and the Gold it Holds
• MiningNewsBreaks - Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Reports High-Grade Tin Intersections at Iska Iska Project

Standard Lithium Ltd. (NYSE American: SLI)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (NYSE American: SLI).

Standard Lithium (NYSE American: SLI) announced that Smackover Lithium, its joint venture with Equinor, has successfully completed the final Direct Lithium Extraction (DLE) derisking step for the South West Arkansas (SWA) project. In partnership with Koch Technology Solutions, the JV's onsite DLE field-pilot plant exceeded key performance benchmarks, achieving over 99% lithium recovery—well above the 95% design target. The pilot plant processed more than 100,000 gallons of brine, producing 970 gallons of concentrated lithium chloride solution, which has been sent to third-party vendors for conversion into battery-quality lithium carbonate. This milestone paves the way for Smackover Lithium to advance into the FEED and feasibility study phase, marking a significant step toward commercialization.

To view the full press release, visit https://ibn.fm/7KIrX

Standard Lithium Ltd. (NYSE American: SLI) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (NYSE American: SLI), closed Tuesday's trading session at $1.33, up 8.1301%, on 3,919 volume. The average volume for the last 3 months is 1,088,524 and the stock's 52-week low/high is $1.05/$2.64.

Recent News

• Standard Lithium Ltd. (NYSE American: SLI) - GreenEnergyBreaks - Standard Lithium Ltd. (NYSE American: SLI) Achieves Key Milestone in Smackover Lithium JV DLE Process 
• GreenEnergyBreaks - Standard Lithium Ltd. (NYSE American: SLI) to Participate in 37th Annual Roth Conference 
• InvestorNewsBreaks - Standard Lithium Ltd. (NYSE American: SLI) Advances Exploration at South West Arkansas Project